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Most current Alzheimer’s disease (AD) therapies in advanced phases of development target amyloid b-peptide
(Ab) production, aggregation, or accumulation. Translational models suggest that anti-Ab therapies may be
highly effective if tested as agents to prevent or delay development of the disease or as therapies for asymp-
tomatic patients with very early signs of AD pathology. However, anti-Ab therapeutics are currently being
tested in symptomatic patients where they are likely to be much less effective or ineffective. The lack of align-
ment between human clinical studies and preclinical studies, together with predictions about optimal trial
design based on our understanding of the initiating role of Ab aggregates in AD, has created a treatment versus
prevention dilemma. In this perspective, we discuss why it is imperative to resolve this dilemma and suggest
ways for moving forward in the hopes of enhancing the development of truly effective AD therapeutics.Introduction
Effective therapy for Alzheimer’s disease (AD) is a major unmet
medical need. The major demographic risk for development of
AD is age with risk doubling approximately every 5 years after
age 65 such that by the age of 85, one’s chances of having
dementia due to AD ranges from 25%–40%. Therefore, the prev-
alence of AD is expected to double every 20 years, largely
because of an anticipated increase in the average expected life
span. Based on estimates that 35 million people worldwide
haveAD today, it is predicted thatwell over 100million individuals
will have AD in 2050 (Alzheimer’s Association, 2010; Wimo et al.,
2010). If nothing is done, the personal, economic, and societal toll
of the ongoing and growing AD epidemic will be immense.
Although key aspects of AD pathogenesis remain enigmatic,
scientific advances over the last 25 years have provided sound
rationale for the development of potentially disease-modifying
AD therapies (Golde, 2005; Selkoe, 2001). These therapies
primarily target the suspected trigger(s) of the disease. Thera-
pies that have advanced the farthest have primarily been devel-
oped based on the proposed initiating role of amyloid b-protein
(Ab) aggregates (Golde et al., 2010). These therapeutic
advances, coupled with advances in early detection of AD-
related pathology in nondemented individuals, suggest that
concerted translational research efforts focusing on prevention
or early intervention could dramatically reduce the incidence
and prevalence of AD. However, current trial design involves
treatment of symptomatic patients, a setting where failure to
show efficacy may be even more likely given the disease
progression. Misalignments of the rationale for the therapy, its
preclinical testing, and the actual testing of the therapy in human
AD clinical trials have resulted in barriers to effective drug devel-
opment that we must recognize and that will be very challenging
to solve.This perspective will focus on how this dilemma in AD transla-
tional research has evolved. We begin by summarizing both the
current state of AD therapeutic development and the paradigm
shift that is occurring with respect to being able to detect and
track underlying AD-related pathologies in humans in the
absence of significant cognitive impairment, as both of these
issues are critical to how the dilemma has arisen and how we
might solve it. We next focus on the core issue of the mismatch
between the design of preclinical studies that evaluate potential
AD therapies and the current translation of those therapies to
human clinical trials. We conclude with a discussion of the
main obstacles that must be overcome to solve this dilemma
and create the desired paradigm shift in translational AD
research.
The Current State of AD Therapeutics and Therapeutic
Discovery
For the typical AD patient, current symptomatic therapies
(acetylcholinesterase inhibitors and memantine), demonstrate
only minimal to modest symptomatic benefit that is not sus-
tained. Moreover, there is virtually no evidence that either of
these types of treatments significantly alter disease progression
(Schneider et al., 2011). Although there is renewed effort to
develop novel cognitive enhancing agents that target different
pathways, only one of these, a repurposed drug, dimebon
(Doody et al., 2008), has entered phase 3 efficacy studies in
humans. Results from the first phase 3 study designed to confirm
promising phase 2 results, unfortunately, showed no evidence of
efficacy (Jones, 2010).
A large percentage of current therapeutic development in AD
is focused on therapies that target the Ab peptide or Ab aggre-
gates (Golde et al., 2010). Accumulation of fibrillar Ab aggregates
in senile plaques within the brain parenchyma is one of theNeuron 69, January 27, 2011 ª2011 Elsevier Inc. 203
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of the proteolytic processing that releases Ab from the amyloid
precursor protein (APP) and its subsequent aggregation in the
brain has provided a number of approaches to what may be
generically referred to as anti-Ab therapy. To date, four general
categories of anti-Ab therapy have been developed: (1) agents
that decrease or modulate Ab production in a manner that is
designed to prevent or slow Ab aggregation and accumulation,
(2) therapies that degrade or enhance clearance of Ab aggre-
gates, (3) therapies designed to block Ab aggregates, and (4)
therapies designed to neutralize toxic Ab aggregates.
The rationale for these anti-Ab therapies has been validated in
preclinical models over the last 20 years and is rooted in the
amyloid cascade hypothesis of AD (Hardy and Selkoe, 2002;
Hardy and Higgins, 1992). This hypothesis posits that accumula-
tion of Ab aggregates in the brain triggers a complex neurode-
generative cascade, which results in progressive cognitive
impairment and dementia. Though the original amyloid hypoth-
esis has been expanded to encompass the likely possibility
thatmultiple different types of Ab aggregates (intracellular aggre-
gates, oligomers, fibrils, and protofibrils) contribute to the
cascade (Walsh and Selkoe, 2004), the essential tenants of this
hypothesis remain the same. The main support for the hypoth-
esis has come from a convergence of genetic, cell biological,
animal modeling, pathological, and biophysical studies. Collec-
tively, these studies demonstrate a primary effect of genetic
alterations that cause familial forms of AD is to alter Ab produc-
tion or Ab itself in a way that promotes its aggregation and
accumulation in the brain (Selkoe, 2001). Additional indirect
support for the hypothesis has come from studies of other
central nervous system (CNS) proteinopathies (Forman et al.,
2004; Ross and Poirier, 2004). A common theme in many neuro-
degenerative diseases is that genetic mutations, overexpression
(often due to gene duplication), ineffective removal, or age-asso-
ciated changes result in accumulation of alternatively folded
protein aggregates that sequentially trigger a degenerative
cascade, neuronal demise, and ultimately regional or wide-
spread brain organ failure. In this regard, the British and Danish
familial dementias are notable with respect to the parallels with
AD in both clinical and pathological features and hypothesized
mechanism (Ghiso et al., 2006). The key difference between
these two familial dementias and AD is that the trigger for the
former appears to be accumulation of different mutant amyloido-
genic peptides derived from the BRI2 (ITM2B) protein versus the
Ab peptide.
The Ab Aggregate Hypothesis Is Reflected by Biomarker
Studies in Humans
Recent biomarker and imaging studies in living humans, along
with classic postmortem studies from Braak and Braak (1997),
the Religious Order Study, and other human studies (Bennett,
2006; Blennow, 2004; Jack et al., 2009; Morris and Price,
2001; Perrin et al., 2009; Schneider et al., 2009; Shaw et al.,
2009), have begun to frame a theoretical average timeline for
the development of various pathological features that charac-
terize AD and the relationship to initial diagnosis of dementia or
prodromal dementia (i.e., mild cognitive impairment due to
AD). Cross-sectional and ongoing longitudinal biomarker studies204 Neuron 69, January 27, 2011 ª2011 Elsevier Inc.reveal that the diagnosis of AD occurs after a relatively long
prodromal clinical phase, which by itself requires the presence
of a dementia syndrome manifested by cognitive impairment
that interferes with many aspects of daily function.
Although the human AD biomarker and imaging cascade is
sure to be refined and advanced, the current data strongly
support the following hypothetical scenario. First, in normal
elderly individuals destined to develop AD, Ab aggregate accu-
mulation begins in the brain ten or more years before the onset
of dementia as a result of reduced clearance or increased
production. As the Ab pathology progresses, clinical correlates
of Ab accumulation, such as amyloid plaques visualized by
radioligand imaging or low cerebrospinal fluid (CSF) Ab42
concentrations possibly due to sequestration in the brain can
be detected. Within an estimated timeline of 10–15 years, Ab
accumulates to levels that are present in brains of AD individuals.
Accumulation of Abmay plateau, though these observations are
based on cohort studies and ongoing longitudinal amyloid
imaging studies will be needed to validate both the time course
and the kinetics of accumulation. During this protracted phase
of progressive Ab accumulation in brain, a number of poorly
understood cellular changes take place reflecting increasing
neuronal injury. For example, there is an increase in CSF total
tau and phosphorylated tau levels that probably reflects synaptic
loss and neuronal demise in brain parenchyma. Coincident or
shortly after tau CSF levels rise, structural magnetic resonance
imaging (MRI) can reveal regional brain atrophy, and functional
MRI can show evidence for altered network activity between
brain regions. Cognitive function and instrumental activities of
daily living may deteriorate but generally still fall within a normal
range. More commonly, subtle memory impairments might be
detected, with more severe cognitive changes and overt
dementia occurring later. This concept that very early, prodromal
AD andmild cognitive impairment phases can be detected years
before dementia becomes apparent has led to two workgroups
proposing new guidelines that put the clinical evolution of AD
on a continuum that starts with a preclinical phase during which
the Ab pathology of AD can be detected, followed by evidence of
neurodegeneration, both without any clinical findings, followed
by the earliest clinical signs (Dubois et al., 2010) (http://www.
alz.org/research/diagnostic_criteria; Figure 1).
The remarkable parallels between the hypothesized cascade,
experimental evidence from animal models, and measurable
biological events occurring in humans, reinforce the rationale
for anti-Ab therapeutics. However, the cascade hypothesis
only predicts that if Ab accumulation in the brain is attenuated
or prevented, then so too will be the subsequent development
of AD. It remains an open question whether targeting Ab aggre-
gates at any stage in the pathological process will result in clin-
ically effective therapeutics. For example, intervention with an
anti-Ab therapy in the disease state with longstanding amyloid
deposited in plaques, substantial synaptic loss and neurodegen-
eration, and manifest clinical symptoms may be completely
ineffective. Even fairly early intervention in nondemented
individuals (Figure 1, stage 2) in which the neurodegenerative
disease process has started may be ineffective. It is possible
the degenerative changes will continue regardless of whether
the therapeutic agent decreases Ab production or even clears
Figure 1. Preclinical AD
The newly proposed staging of preclinical or
prodromal AD reflects a cascade beginning with
Ab accumulation in the brain of clinically asymp-
tomatic individuals and inexorably progressing
to AD.
Neuron
PerspectiveAb deposits from the brain. In general, given the reasonable
possibility that some aspects of the neurodegenerative cascade
may be self-reinforcing, become independent of the initial
trigger, or are irreversible in nature, one might predict that
anti-Ab therapies will be increasingly ineffective in terms of atten-
uating the course of illness as the underlying pathology prog-
resses and clinical symptoms emerge. Ultimately, the true test
of the cascade hypothesis is to conduct a true primary preven-
tion trial with anti-Ab therapy in patients destined to develop
AD but prior to the onset of measureable Ab deposition. Alterna-
tively, one might envision that the hypothesis could be reason-
ably well tested in secondary prevention (very early intervention)
trial in subjects with Ab pathology only, prior to the neurodegen-
erative phase (preclinical stage 1). In the later scenario, the test
potentially would be more effective if the therapeutic modality
enhanced clearance of Ab.
Critiques of the Ab Aggregate Hypothesis
In order to conduct a primary prevention study with a therapeutic
agent for any disease, one needs a strong scientific rationale.
Although the Ab aggregate/amyloid hypothesis is not without
its critics, it has very strong scientific underpinnings. In the
context of trying to move the field toward primary prevention
studies with anti-Ab therapies, it is important to consider the
views of those who are skeptical about the role of Ab in AD.
One valid critique of the hypothesis is that most of the experi-
mental evidence supporting the hypothesis comes from the
study of the genetic alterations that cause familial autosomal
dominant AD (Selkoe, 2001; Younkin, 1998). Thus, a key
assumption is that pathological cascades in sporadic AD are
the same as in familial AD. Given that the typical genetic and
sporadic forms of AD are very similar with respect to postmortem
findings, clinical course, and evidence from the emergingNeuron 69biomarker and imaging cascade in
sporadic AD, this seems a reasonable
assumption (Shepherd et al., 2009).
Indeed, when examples from other
human diseases with genetic and
sporadic forms, such as hypercholester-
olemia and prion diseases, are consid-
ered, this concept is quite tenable (Brown
and Goldstein, 1986; Prusiner, 1998).
Nevertheless, because of the late age of
onset, sporadic AD is not a completely
uniform clinical or pathological entity: it
is complicated by other systemic or
CNS illnesses and conditions, and the
biological processes of aging. Thus, the
underlying brain pathology that results in
clinical dementia may represent theconvergence of independent processes and not necessarily
a single pathologic entity (Small and Duff, 2008), as thought to
be the case in early onset familial AD. Indeed, in the over-80-
year-old population who have died with a clinical diagnosis of
probable AD dementia, postmortem phenotypes often show
not only plaques and tangles pathology characteristic of AD,
but other proteinopathies and vascular insults as well (Dickson,
2001). However, even if this is the case, andmultiple pathologies
synergize in some subpopulations of those affected with what
we define as AD, one might still predict that preventing Ab depo-
sition would have substantial, but perhaps not complete, effi-
cacy.
Another critique of the Ab cascade hypothesis arises from the
imperfect correlation between cognitive status and Ab deposits
in the brain, and the postmortem findings of significant Ab accu-
mulation in the brains of elderly who were cognitively intact
shortly before death (Bennett et al., 2006; Giannakopoulos
et al., 2003; Na¨slund et al., 2000). The criticism that follows is
Ab deposition itself does not necessarily predict or cause clinical
AD. Such observations, however, can be understood in several
other ways. First, there may be a threshold effect that involves
the density and duration, or even rate of Ab accumulation that
together with the age of onset of the pathological processes
determines the onset of the clinical manifestations of AD.
Second, as with other illnesses, there are almost certainly
genetic, pathological, epigenetic, and environmental mediators
that modulate progression, disease course, and manifestation
of illness. For example, one proposed mediator involves the
concept of ‘‘cognitive reserve’ that hypothesizes that factors
that enhance neuroplasticity and synaptogenesis, may make
an individual more resistant to the clinical manifestations of the
underlying neuropathology, thereby delaying onset of the clinical
expression of the illness (Cummings et al., 1998; Stern et al.,, January 27, 2011 ª2011 Elsevier Inc. 205
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ment of AD that we might now refer to as preclinical stage 3 is
often not recognized in elderly people who die and come to
autopsy. Some evidence for this is from the Religious Order
Study where those who died without cognitive impairment and
who had intermediate or high likelihood of AD based on neuro-
pathological examination scored 0.25 standard deviation lower
on episodic memory tests than those without pathology (Bennett
et al., 2006), worsening of episodic memory being the earliest
and most characteristic cognitive phenotype for AD (Dubois
and Albert, 2004).
Finally, it has become common to explain the results from
failed AD therapeutic trials with presumptive anti-Ab therapies
as evidence that the hypothesis is wrong. This is clearly inaccu-
rate, as to date, such trials were not definitive tests of the
cascade hypothesis, but rather expedient ways to test poten-
tially disease-modifying AD therapeutics in the current clinical,
regulatory, and fiscal environment. None of the putative anti-
Ab agents that have failed in pivotal phase 3 therapeutic trials
were optimal or even optimized agents within their class of
anti-Ab therapeutics: Alzhemed (tramiprosate, homotaurine)
was a weak aggregation inhibitor; Flurizan (tarenflurbil, R-flurbi-
profen) was a g-secretase modulator with low potency and poor
brain penetration; and semagacestat, a nonselective g-secre-
tase inhibitor (GSI), had significant mechanism-based toxicity
limiting its dosage and efficacy with respect to lowering Ab
production (Golde et al., 2010). None of these drugs showed
efficacy against primary endpoints in phase 2 trials but were
advanced to phase 3 nonetheless.
Other anti-Ab therapies (e.g., Notch-sparing GSIs, humanized
anti-Ab monoclonal antibodies, and second generation Ab
vaccines) currently in therapeutic trials for AD are more likely to
have improved effects on their respective targets, but it is unclear
whether this will translate to clinical efficacy. These ongoing and
planned trials should provide an answer to the questions raised
above as to whether targeting Ab in symptomatic AD patients
will have any efficacy at all. However, available phase 2 data
would suggest if these compounds are going to have disease-
modifying effects and improve the course of cognitive decline in
this patient population, the effect is going to be quite modest.
Other Therapeutic Approaches
Although most therapeutic activity in AD with respect to poten-
tially disease-modifying therapy has focused on anti-Ab thera-
pies designed to decrease Ab production or aggregate formation
or remove preexisting aggregates, both tau-targeted and more
general neuroprotective agents among others are also being
developed (Golde et al., 2010; Salloway et al., 2008). Develop-
ment of anti-tau therapies has been hindered by a lack of clear
insight into what is the optimal desired effect on tau (e.g.,
decreasing phosphorylation, blocking proteolysis, or preventing
aggregation). Though animal modeling studies do provide
evidence that Ab aggregates promote some aspects of tau
pathology (Go¨tz et al., 2001; Lewis et al., 2001), the precise
mechanistic links between Ab and tau pathologies have not
been established, thus hindering not only our ability to appre-
ciate the biological connection but also to develop better animal
models and identify druggable therapeutic targets.206 Neuron 69, January 27, 2011 ª2011 Elsevier Inc.Neuroprotective strategies are rational approaches but have
generally not gained much traction with little progress in terms
of new investigational drugs for AD (Salloway et al., 2008). The
reasons for this may stem from (1) a lack of understanding
regarding the mechanisms of neural injury, (2) uncertainty
regarding the best targets for neuroprotection in AD, (3) the inad-
equacy of current animal models as exemplified by the relative
paucity of neurodegeneration in transgenic mice that are
primarily models of amyloid deposition and do not exhibit the
full spectrum of AD pathologies, or (4) the poor track record of
successful translation of neuroprotective drugs from the preclin-
ical to clinical phase in other neurological disease such as stroke
or any neurodegenerative condition.
In any case, if one assumes the temporal sequencing in the Ab
aggregate cascade is correct, then one would predict that anti-
tau therapy will be most effective in the very early pathological
phases of the disease and not after the stage when robust Ab
deposition, synaptic loss, and neurofibrillary changes have
begun. In contrast, general or focused neuroprotective strate-
gies might be efficacious even in such later stages, as there is
evidence for continued neuronal demise as the clinical dementia
worsens.
The Treatment versus Prevention Dilemma
The preceding overview of the status of AD therapeutics high-
lights what can be referred to succinctly as the treatment versus
prevention dilemma. Of primary importance is the point that
anti-Ab therapy is most likely to show efficacy in a primary
prevention setting. Certain therapeutic modalities that can result
in Ab clearance could also show efficacy in Ab deposition stages
of AD. However, current clinical trials designs have involved
treatment of patients with AD dementia or mild cognitive impair-
ment over generally 18 month to 4 year intervals (Schneider and
Sano, 2009). In these instances, one might predict that the likely
outcome of anti-Ab therapy will be no observable beneficial
clinical effect. Testing anti-Ab therapy in patients with clinically
diagnosed AD may be analogous to treating a patient with
atherosclerosis, myocardial infarctions, and heart failure with
a cholesterol-lowering agent and expecting his current cardiac
function and subsequent clinical course would noticeably
improve. In such a setting, targeting the trigger of disease, or
the pathophysiologic process that is protracted, is not likely to
demonstrate efficacy. Indeed, one can speculate that if the early
trial designs for the testing of statins were in patients in complete
cardiac failure and used morbidity and mortality endpoints (as
opposed to plasma cholesterol lowering), it is likely that statins
would have failed to show efficacy. Though statins clearly lower
cholesterol, even today it is challenging to demonstrate that sta-
tin treatment has significant impact on cardiovascular morbidity
and mortality in nonselected patient populations.
Not only does the amyloid cascade hypothesis provide
support for initiation of primary prevention or possibly very early
intervention (secondary prevention trials) with anti-Ab therapy,
but preclinical studies in Ab-depositing transgenic mouse
models do as well (Ashe and Zahs, 2010). The vast majority of
preclinical studies in APP transgenic mice that show efficacy
are equivalent to primary or secondary prevention, as treatment
is typically begun either before the onset of amyloid pathology or
Neuron
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models only appear to be good models of preclinical AD
because they show amyloid deposition, amyloid-associated
neuritic dystrophy, and plaque associated micro- and astroglio-
sis (Price and Sisodia, 1998) but typically no neurodegenerative
phenotypes and minimal tau pathology. Thus, any study at any
age in thesemice mainly reflects likely outcomes in early preclin-
ical stages of AD. Although many models do show cognitive
impairments that can be interpreted to be reminiscent of AD in
that they involve memory systems, the cognitive changes and
their relationship to other pathological features vary from model
to model, have inconsistent relationships with amyloid and other
pathologies, and can often be rapidly reversed (Ashe, 2001).
Lastly, treatments given to APP transgenic mice when amyloid
deposition and associated pathology are established are gener-
ally less effective (Abramowski et al., 2008; Das et al., 2001).
Thus, it is uncertain whether efficacy with respect to alleviating
the behavioral changes observed in such mouse models, espe-
cially performed in preplaque stages, would be able to predict
efficacy with respect to behavioral alterations in humans with
symptomatic AD.
Recognizing and Overcoming the Medical
and Scientific Obstacles to Solving
the Treatment versus Prevention Dilemma
There are two straightforward ways to solve the dilemma through
medical and scientific progress. First, with anti-Ab therapies and
perhaps anti-tau therapies,weshould conduct primary prevention
or intervention trials in minimally affected individuals (secondary
prevention in stage 1/2). A second, alternative, strategy would
be to develop therapies more likely to work in symptomatic
patients (i.e., in a preclinical stage 3 or prodromal AD).
When considering primary prevention or very early intervention
in asymptomatic subjects, the key scientific issue will be whether
a therapy canbedeveloped that hits the target sufficiently to have
a very good chance for disease modification and is sufficiently
safe for use in people included in the trial but not destined to
develop AD or likely to develop the clinically symptomatic illness
only after several years of good health.Whether a candidate drug
can be considered sufficiently safe will depend on (1) the under-
lying biology of the target (mechanism-based toxicity), (2) the
ability to avoid off-target effects, and (3) an empirically deter-
mined assessment of benefit versus liabilities. Whether a therapy
is safe enough will also be influenced by the conditions of use,
whether one is considering a true primary prevention trial, a trial
in preclinical AD, or a trial in established symptomatic AD, as
the risk to benefit profile will shift toward tolerating greater risk
with advancing clinical disease. In the later populations, the bar
for safe enough is lower given the evidence for irreversible though
protracted progression.
Many current anti-Ab therapeutic modalities fail the safe
enough test even in symptomatic patients, especially given the
long-term treatment that is necessary in this chronic condition.
However, a number of modalities, such as selective g-secretase
inhibitors, g-secretase modulators, and second or third genera-
tion vaccines, theoretically hold some promise for meeting the
safe enough requirement for testing as prophylactic agent
(Golde et al., 2010).From a medical perspective, a key issue will be whether the
community will accept the concept of presymptomatic AD,
which, to reiterate, is the presence of Ab aggregate accumula-
tion with or without some evidence for neurodegeneration in
the absence of detectible cognitive symptoms. This diagnostic
construct is invaluable when considering moving toward primary
prevention or early intervention trials as it potentially identifies
the earliest manifestation of the disease. As noted previously,
preclinical AD may exist for a decade or more before what has
been referred to as prodromal AD or mild cognitive impairment
due to AD, providing a window of opportunity for intervention.
Preclinical AD also represents the boundary condition between
two important therapeutic approaches: the true primary preven-
tion of illness and the so-called ‘secondary prevention’ or treat-
ment of the very earliestmanifestations of illness. Future trials will
need to account for and distinguish between the truly asymp-
tomatic and preclinical AD.
Although we have seen remarkable and rapid advances in the
ability to diagnose preclinical AD (Weiner et al., 2010), in order to
move toward primary prevention we need to advance our ability
to predict who is at very high risk for AD and in what time frame
they might develop observable pathology and subsequently
clinical symptoms. Based on current data, we know that APOE
34 genotype, low CSF Ab42, and increased PET amyloid tracer
binding in the brain, all confer substantially increased risk for
the progression of preclinical AD to mild cognitive impairment
(MCI) and MCI to AD (Blennow, 2004; De Meyer et al., 2010;
Romas et al., 1999; Storandt et al., 2009). But these markers
do not provide information regarding onset of pathology. Even
the presence of an APOE 34 genotype only indicates increased
risk or earlier age-of-onset but fails to provide precise informa-
tion with respect to timing of disease onset. Identification of
additional factors that predict more precisely the risk for devel-
opment of AD, what are generically referred to as premorbid
biomarkers, could be very useful in identifying an at-risk popula-
tion for a primary prevention study. Again, if we make an analogy
to atherosclerotic disease, plasma cholesterol-testing serves as
such a premorbid biomarker.
Given this reality, there is substantial interest in the field to test
preventive agents in genetic forms of AD where large kindreds,
such as one in Antioquia, Colombia, with a deterministic early-
onset presenilin 1 mutation (www.dian-info.org), or in individuals
who are homozygous for the APOE 34 allele (Reiman et al., 2010;
Strittmatter and Roses, 1995). Though laudable and perhaps
the only way forward at the present time, these studies have
some limitations. Even in large kindreds with deterministic
AD-causing mutations, the number of asymptomatic mutation
carriers who might be predicted to develop or have preclinical
AD within a reasonable time frame is relatively small. Thus, the
number of different therapies that might be tested in such
a setting will probably be very limited and, because of variance
in the age of onset, it is unclear how long such studies would
need to extend in order to convincingly demonstrate efficacy.
Further, it has been shown that some anti-Ab treatments may
have altered efficacy in presenilin mutation carriers (Weggen
et al., 2003).
The 1%–2% of the population that is homozygous for the
APOE 34 allele represents another at-risk or preclinical sampleNeuron 69, January 27, 2011 ª2011 Elsevier Inc. 207
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increases risk for AD by 15 times compared to APOE 33 or 32
carriers (Farrer et al., 1997; Reiman et al., 2010). Simple genetic
screening could theoretically provide cohorts for selection of trial
participants with this geneotype. However, the low frequency of
homozygous APOE 34 carriers severely limits their recruitment
and possibly even generalizability to the population as a whole.
Choosing such samples as familial early onset AD or people
who are homozygous APOE 34 carriers as the intent-to-treat
population also raises another issue, which is whether the
expected action of the drug is influenced by the genetic makeup
of the individuals. For example, presenilin-linked AD is associ-
ated with altered Ab42 production (Selkoe, 2001), while APOE
34 is associated with decreased clearance of Ab from the brain
(Holtzman et al., 2000).
APOE 34 heterozygotes are another at-risk potential sample
for prevention trials: these individuals constitute approximately
24%–30% of the population, have three times the risk for AD,
about a 10 year lower age-of-onset compared to APOE 33 or
32 carriers (Farrer et al., 1997), and represent50% of AD cases
(Roses, 1997). Although they have one-fifth the risk for AD
compared to 34 homozygotes, they are more than eight times
easier to recruit by virtue of their prevalence. Thus, a prevention
trial with heterozygotes may be carried out efficiently and be
more generalizable to the majority of AD patients.
In many scenarios, a 15–20 year timeline would be the
minimum time to test, possibly retest, and widely deploy an
effective true primary prevention therapy or a therapy for the
clearly asymptomatic preclinical stages of AD. In the interval,
millions of people will continue to develop AD. So what do we
do for them? First, we can simply hope that the predictions of
the cascade hypothesis are wrong and that trigger-targeting
therapy will show better efficacy in current trials than might be
predicted. Evidence for efficacy and safety would probably
mean much more rapid approval for symptomatic use. Second,
we can renew our efforts to identify novel downstream targets
and develop novel neuroprotective or regenerative therapies
that may be more efficacious than targeting upstream pathways
in true treatment trials. These studies would be greatly facilitated
by the development of animal models that recapitulate the full
disease phenotype.
An important area where the medical and scientific field can
improve in order to overcome the treatment versus prevention
dilemma is to better align the design of preclinical studies with
subsequent clinical trial designs. This means that the usual
chronic dosing studies in pre- or early amyloid-depositing APP
transgenic mice with anti-Ab therapy must be accompanied or
replaced by studies in which the mice have AD-like Ab loads at
the time the treatment is initiated. Given that in practice we
have not had animal models that recapitulate the entire AD
degenerative cascade (Ashe and Zahs, 2010), there are some
practical limitations as to how far one can take this realignment.
Thus, we cannot truly evaluate the potential of anti-Ab or neuro-
protection therapies to halt neuronal loss because there is such
limited neuronal loss in current APP mouse models. Neverthe-
less, we can at least attempt to be more rigorous and self-critical
with respect to the potential clinical translation of preclinical
data.208 Neuron 69, January 27, 2011 ª2011 Elsevier Inc.Recognizing and Overcoming the Other Obstacles to
Solving the Treatment versus Prevention Dilemma
There are many nonscientific and nonmedical challenges to im-
plementing primary prevention or early intervention in AD. Some
of themost challenging aspects are financial in nature; others are
regulatory barriers.
Financial Obstacles
Phase 2 and 3 clinical trials in the pharmaceutical industry overall
are inherently complicated, resource-intensive endeavors with
high probabilities for failure. Together, phase 2 and 3 programs
consume 48% of the costs for each drug launched and may
cost on average $185 million and $235 million, respectively
(Paul et al., 2010). Commercially sponsored AD therapeutic
programs and most prevention trials are typically more expen-
sive. It is difficult to source the costs of an AD prevention trial
for industry as only one such trial has been sponsored: a Ginkgo
biloba extract study in France involving about 2800 patients over
5 years (Vellas et al., 2006b).
TheNational Institutes of Health has funded several prevention
trials including Women’s Health Initiative-Memory Study
(WHIMS), the Alzheimer’s Disease Anti-inflammatory Prevention
Trial (ADAPT), Ginkgo Evaluation of Memory Study (GEM) and
PreAdvise (Craig et al., 2005; Kryscio et al., 2004; Martin et al.,
2002; Snitz et al., 2009). These trials were designed in a manner
that cost significantly less than current industry-funded treat-
ment trials (Table 1). For example, some of the studies enhanced
the likelihood for AD by choosing participants who were at
higher risk or who already had MCI, outcomes were onset of
AD or MCI, they had relatively short follow up periods of 4 to
7 years, and they did not incorporate the comprehensive
biomarker or imaging assessments that are available today.
This enabled recruitment of 2500 to 4500 participants. Based
on publicly listed sources (http://www.projectreporter.nih.gov/
reporter.cfm), the comparably large ADAPT (Lyketsos et al.,
2007) and GEM Ginkgo biloba extract study (DeKosky et al.,
2008) studies have respectively received approximately
$44 million and $28 million of total funding. Total costs for these
studies are likely higher as they typically leverage infrastructure
within the National Institutes of Health and participating
academic institutions. Taken together, it is reasonable to esti-
mate that a federally-sponsored prevention trial would cost
around U.S. $80–100 million for a 5 year U.S. study. Given this
fiscal reality, we must explore ways to run well-powered primary
prevention or early intervention studies that do not cost substan-
tially more or even cost less. However, this will be challenging as
biomarkers, imaging, or both will probably be needed to both
select and stratify the sample population.
In reality, these aforementioned trials were not exclusively
primary prevention trials, with varying mixtures of enrolled
participants ranging from subjects without AD pathology to
others with varying degrees of preclinical AD pathology and
others with MCI. Given that these trials largely lacked ancillary
biomarker and imaging studies, one can speculate that the trial
participants who developed significant symptoms of AD in the
first few years of such trials probably had significant AD
pathology at the time of enrollment. Without a biomarker- and
imaging-based stratification, mixed disease status at enrollment
will complicate trial design by creating uncertainty regarding
Table 1. AD Prevention Studies
Study Inclusion Criteria
Age
(years)
Sample
Size
Length
(years) Outcomes Status
ADAPT/naproxen,
celecoxib (Meinert
et al., 2009)
First degree relative
with AD
R70 2,528 5–7 AD, cognitive decline Early termination
GEM/Ginkgo biloba
(Snitz et al., 2009)
Asymptomatic
60%, MCI 40%
R75 3,072 5 AD, cognitive decline,
cardiovascular
No significant effects
GUIDAGE/Ginkgo biloba
(Vellas et al., 2006a)
Memory complaints >70 2,854 4 AD No significant effects
Physicians Health
Study-II/vitamin E,
folate, b-carotene
(Christen et al., 2000)
Asymptomatic >65 10,000 9 Telephone cognitive
testing
Ongoing
Heart Protection Study/
vitamin E, C, b-carotene,
simvastatin (H.P.S.C.
2002a, 2002b)
Asymptomatic
with cardiovascular
risk factors
40–80 20,536 5 AD, telephone interview
for cognitive status (TICS)
No differences
PreAdvise/selenium,
vitamin E (Kryscio
et al., 2004)
Asymptomatic,
males only
R60 10,400 9–12 Dementia onset,
cognitive tests
Terminated
HERS/estrogen
medroxyprogesterone
(MPA) (Grady et al., 2002)
Asymptomatic,
females
mean = 67 1,060 4.2 Cognitive tests Improvement on one test
WHIMS/estrogen and
MPA (Craig et al., 2005)
Asymptomatic,
female
65–80 4,532 4–5 AD and MCI, cognitive
scores (add on)
Increased risk for MCI/AD,
worse scores with HRT
WHIMS/estrogen alone
(Craig et al., 2005)
Asymptomatic,
female
65–80 2,497 4–5 AD and MCI, cognitive
scores (add on)
Increased risk for MCI/AD,
worse scores with HRT
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Perspectivegroup size and length of trial and also potentially confounding
results.
Biomarkers and imaging, as discussed more extensively
below, are likely to be essential for future prevention trials,
perhaps to either exclude (primary prevention) patients with
prodromal AD or select (secondary prevention) participants at
risk for progression to symptomatic AD or for use as a surrogate
outcome instead of assessing clinical status, and the costs
and complexity will rise. Further, the duration of a primary or
secondary prevention trial is far longer than what the commercial
sector is generally willing to entertain. Thus, novel prevention
trials and cost-sharing models need to be explored that involve
public and private sector partnership with shared risks and
shared rewards. On a much smaller financial scale, such a
cost-sharing model has been successfully implemented with
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and
the returns have exceeded most investigators’ initial hopes,
although ADNI is not a clinical trial (http://www.adni-info.org/).
Other financial considerationsdealwith patents andexclusivity
of marketing a new therapy for AD. As noted above, the financial
resources required to conduct primary prevention or early inter-
vention trials in AD are going to be substantial, and they are
certain to takemany years to reach ameaningful result. If patents
expire during or shortly after clinical testing, a high probability
when conducting primary or secondary prevention studies, and
exclusivity is limited or nonexistent, then private sector devel-
opers of AD therapies will be reluctant to conduct primary or
secondary prevention trials in AD as the return on investmentwould be limited and not justify the risks. The sufficient return
on investment issue is a sensitive one. In our current drug devel-
opment environment, we need to revisit the legal policies that
would discourage investment in primary prevention studies.
Such policies need to transparently balance public health needs
with private sector marketplace driven incentives. These issues
are of course not restricted to AD but germane to our broader
efforts to move away from a health care system that is designed
to treat the sick, to one that tries to maintain our wellness.
Regulatory Considerations
Coupled with these financial obstacles are regulatory and meth-
odological obstacles that deal with acceptable trial design.
Current Food and Drug Administration regulatory guidelines for
AD require that a drug show benefit for patients with AD
dementia on cognition and that clinical benefit be demonstrated
either by global or staging assessment or in activities of daily
living (ADL). For example, nearly all 18-month-long trials for
mild or for mild tomoderate AD used the ADAS-cog as the cogni-
tive measure and the Clinical Dementia Rating or an ADL scale
for the test for clinical significance (Schneider and Sano, 2009).
The trials that tested cholinesterase inhibitors for mild cognitive
impairment used the onset of AD dementia as the primary
outcome supported by required improvement on a cognitive
test (Raschetti et al., 2007). If such cognitive and functional
measures are required in the design of primary or secondary
prevention trials, they will probably require nearly 10 or more
years to conduct. To adequately power such a study will be chal-
lenging and add significant and possibly insurmountable costs.Neuron 69, January 27, 2011 ª2011 Elsevier Inc. 209
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would be done to support an indication or label such as, ‘‘drug
X is indicated for the treatment of patients at risk for AD (or
have preclinical AD) to delay the onset of prodromal AD or atten-
uate the course of cognitive impairment.’’ Such an indication
would break new ground as it would define a particular at-risk
state defined by biomarkers and outcomes that fall short of
currently recognized clinical states or diagnoses such as AD
dementia. This requires, however, that the at-risk state or marker
be recognized and validated as defining the target population for
the drug and that the outcomes of cognitive change or onset of
a subtle clinical state such as mild cognitive impairment be
accepted as legitimate outcomes by regulators.
For early phase prevention trials, changes in the nonclinical
endpoints can be reasonably accepted if the change is predic-
tive of a clinical outcome. For AD, however, this would require
demonstration that, for example, reductions in brain amyloid
tracer due to an experimental drug are associated with subse-
quent attenuation of cognitive decline or improved quality of
life. At present, it is uncertain whether current AD biomarkers
can be used as surrogates for clinical measures. Indeed, at
this point the field is trapped by a conundrum; we would like to
use biomarkers as surrogates in clinical trials, but we have yet
to definitively establish the link between the surrogate marker
with cognitive or functional endpoints.
Next Steps: How Do We Collectively Ensure that Novel
Therapies Are Tested in the Appropriate Populations?
A largely unspoken concern among many is that AD therapies in
development will demonstrate efficacy against the target or
biomarker (e.g., lower Ab levels, clear Ab deposits from the
brain), meet the ‘‘safe enough’’ requirement, yet fail to show clin-
ical efficacy in clinical trials. Because of economic and regulatory
forces, such clinical failures will result in the termination of devel-
opment of the drug. But, if tested in a primary prevention or early
intervention trial, the therapy might show remarkable efficacy.
Clearly, no one wants this very plausible hypothetical situation
to become reality. In order to prevent this from happening we
outline some of the key next steps.
First, we must continue the funding of studies that are needed
to prove biomarkers can be used as endpoints and represent
truly valid clinical surrogate endpoints. Given the cost and risks
associated with developing drugs for prevention of AD, it is
likely that the development process will need to be staged
and all phases of the approach linked to biomarkers. In the first
stage, premorbid biomarkers for the pathology of AD would be
used to select patients or enrich a sample for likelihood of
progression to AD in a reasonable time-frame. Examples of pre-
morbid biomarkers for primary prevention studies might be
those based on APOE genotype alone or more extended geno-
types that might emerge from ongoing genome-wide associa-
tion studies. For secondary prevention studies, one might
consider diagnostic biomarkers such as CSF Ab, tau, or both
or imaging studies such as FDG-PET profile, brain amyloid
load, or hippocampal or medial temporal lobe volume. In either
case, more than one biomarker may be needed to better
identify an asymptomatic risk state or preclinical AD that is
currently defined only as a biomarker positive risk state. In the210 Neuron 69, January 27, 2011 ª2011 Elsevier Inc.second stage, biomarkers will be needed to demonstrate that
the therapy is appropriately modifying the target. For example,
with an anti-Ab antibody-based therapy, a decrease in brain
amyloid tracer retention with an Ab antibody therapy would indi-
cate target engagement and thereby justify further trials. In the
third stage, biomarkers might be used as surrogate endpoints.
In a primary prevention trial, the endpoint might be time to
conversion to a stage 1 biomarker or, for a secondary preven-
tion trial, time to conversion of a stage 2 biomarker. Although
biomarker-based trials can add substantial costs on a per
subject basis to the trial, these costs might be offset partially
or wholly by possible reductions in length of trial, reductions
in sample size needed, or both. Development of plasma-based
biomarkers that predict preclinical stages of AD could consider-
ably reduce the cost of a biomarker-based prevention trial,
making it much more feasible from an economic point of
view. However, despite intensive efforts, even state-dependent
diagnostic plasma biomarkers that reliably distinguish AD
patients from controls have yet to be developed. In any case,
the knowledge-based, regulatory, and legal issues involved in
using both validated and novel surrogate biomarkers for AD
trials are substantial and require detailed consideration (Katz,
2004).
A biomarker-based approach to AD prevention or early inter-
vention trials will probably increase the costs associated with
the trial and is not without inherent risk. Even if the regulatory
agencies give initial approval of a therapy based on biomarker
outcomes, there would have to be long-term postapproval
efficacy studies (phase 4) that track whether the biomarker effect
led to delay of cognitive impairment and dementia. Only this type
of morbidity data will provide the evidence base for continued
use of the therapy.
Second, we must find ways to ensure that the commercial
sector will invest in prevention trials even if they take 10 or
more years to complete. With huge investments already made
by the commercial sector in novel AD therapeutics, it will not
take too many additional negative trials for the pharmaceutical
industry to significantly reduce their investment in novel AD
therapeutics. To ensure that we have the best possible thera-
pies moving forward, we cannot afford to have the commercial
sector largely abandon their efforts to develop novel AD
therapeutics. The recent history of stroke therapeutics is highly
informative in this regard. As highlighted in a recent review
(O’Collins et al., 2006), out of 114 novel treatments tested in
humans for stroke, only tissue plasminogen activator demon-
strated sufficient efficacy and safety in human studies to be
approved by the Food and Drug Administration. Because of
this poor record of translation, efforts to develop novel stroke
therapies have been severely curtailed in the commercial
sector. The net effect of these negative trials is that the chances
of developing novel breakthrough stroke therapies in the fore-
seeable future have been significantly reduced. The authors
of that review on stroke therapeutics make several conclusions
that are highly relevant to the AD field regarding alignment
of preclinical studies and human clinical trials design. They
suggest that some of the underlying factors that may have
led to the high failure rate of stroke drugs are (1) limited preclin-
ical assessment of many stroke therapies prior to human
Neuron
Perspectivetesting, (2) lack of alignment between the preclinical studies
and the human trials and (3) overall lack of concordance
between efficacy observed in preclinical models and clinical
trial outcomes.
As compared to stroke, where defining a homogenous intent-
to-treat population is extremely challenging, in AD we may have
the tools to identify a well-defined population with respect to
AD-related pathology or lack thereof and also the capability to
design preclinical studies that might more closely match the
pathological state of those enrolled in the trial, at least with
respect to amyloid burdens for anti-Ab therapies. Thus, a third
key step moving forward is to ensure that these kinds of align-
ments, when feasible, occur for investigative new drug
approvals. By insisting that preclinical data and clinical trial
design are aligned, the likelihood of translational success in
novel AD therapeutics might be increased.
Given the recent advances in the AD field, it is reasonable to
believe that many of the medical and scientific advances neces-
sary to conduct prevention studies will be overcome. The
nonmedical challenges that may prove more difficult to over-
come are those regarding the financial underpinnings of preven-
tion or early intervention trials. At present there is no clear road
map regarding how such trials might be financially underwritten
and who receives the financial rewards if a therapy is shown to
have benefit. Moreover, if the scientific and medical advances
result in trial designs that are substantially more expensive,
rather than less expensive, then the financial obstacles will
become greater. Because there is no clear path forward at this
time, a fourth step is to make certain the issues of who pays
and who gets rewarded are openly discussed. Indeed, all the
stake holders need to recognize that this may be a critical issue
to address, not only for AD prevention trials but prevention trials
for many neurodegenerative conditions. Ultimately, addressing
this obstacle may require revisiting patent law and laws or guide-
lines regarding market exclusivity.
A recent report estimated that the current annual worldwide
costs of care for thosewith AD is approximately 1%of theworld’s
GDP (U.S. $600 billion/year; Alzheimer’s Disease International,
2010). Given the enormous economic burden, there is an over-
riding imperative to transcend the obstacles to conducting the
most appropriate trials thatwill have thegreatest potential impact
on the disease for any given novel therapeutic. If we can gain the
scientifically based consensus among the many stakeholders,
then we can collectively develop a road map that addresses the
obstacles highlighted in this review that block conducting the
necessary preventative studies. This road map will be complex
in its formulation as it will need to not only involve physicians,
researchers, and patients and their caregivers but also the
commercial sector, foundations, drugapproval agencies, legisla-
tors, and governments, and be expensive to implement.
However, it is a challenge that we must face and overcome.
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